MCID: CCC001
MIFTS: 53

Coccidioidomycosis

Categories: Infectious diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Coccidioidomycosis

MalaCards integrated aliases for Coccidioidomycosis:

Name: Coccidioidomycosis 12 74 52 58 54 3 43 15 17 71 32
Valley Fever 52 58 42 3
Primary Extrapulmonary Coccidioidomycosis 12 71
Coccidiosis 52 71
Primary Pulmonary Coccidioidomycosis 71
Coccidioides Immitis Infection 52
San Joaquin Valley Fever 58
Acute Coccidioidomycosis 71
Coccidioides Infection 58
Enteric Coccidiosis 71
California Disease 58
San Joaquin Fever 52
Desert Rheumatism 58
Desert Fever 58

Characteristics:

Orphanet epidemiological data:

58
coccidioidomycosis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:13450
ICD9CM 34 114 114.9
MeSH 43 D003047
NCIt 49 C84642
SNOMED-CT 67 60826002
ICD10 32 B38 B38.9
MESH via Orphanet 44 D003047
UMLS via Orphanet 72 C0009186 C0153257 C0851907
Orphanet 58 ORPHA228123
UMLS 71 C0009186 C0009187 C0153257 more

Summaries for Coccidioidomycosis

MedlinePlus : 42 Valley Fever is a disease caused by a fungus (or mold) called Coccidioides. The fungi live in the soil of dry areas like the southwestern U.S. You get it from inhaling the spores of the fungus. The infection cannot spread from person to person. Anyone can get Valley Fever. But it's most common among older adults, especially those 60 and older. People who have recently moved to an area where it occurs are at highest risk for infection. Other people at higher risk include Workers in jobs that expose them to soil dust. These include construction workers, agricultural workers, and military forces doing field training. African Americans and Asians Women in their third trimester of pregnancy People with weak immune systems Valley Fever is often mild, with no symptoms. If you have symptoms, they may include a flu-like illness, with fever, cough, headache, rash, and muscle aches. Most people get better within several weeks or months. A small number of people may develop a chronic lung or widespread infection. Valley Fever is diagnosed by testing your blood, other body fluids, or tissues. Many people with the acute infection get better without treatment. In some cases, doctors may prescribe antifungal drugs for acute infections. Severe infections require antifungal drugs. Centers for Disease Control and Prevention

MalaCards based summary : Coccidioidomycosis, also known as valley fever, is related to coccidiosis and cryptosporidiosis, and has symptoms including arthritis, chest pain and conjunctivitis. An important gene associated with Coccidioidomycosis is CD69 (CD69 Molecule), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Fluconazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and lung, and related phenotypes are hematopoietic system and digestive/alimentary

Disease Ontology : 12 A primary systemic mycosis that results in systemic fungal infection, has material basis in Coccidioides immitis, transmitted by airborne spores and has symptom conjunctivitis, has symptom arthritis, has symptom chest pain and results in formation of skin nodules.

CDC : 3 Valley fever, also called coccidioidomycosis, is an infection caused by the fungus Coccidioides. The fungus is known to live in the soil in the southwestern United States and parts of Mexico and Central and South America. The fungus was also recently found in south-central Washington. People can get Valley fever by breathing in the microscopic fungal spores from the air, although most people who breathe in the spores don't get sick. Usually, people who get sick with Valley fever will get better on their own within weeks to months, but some people will need antifungal medication. Certain groups of people are at higher risk for becoming severely ill. It's difficult to prevent exposure to Coccidioides in areas where it's common in the environment, but people who are at higher risk for severe Valley fever should try to avoid breathing in large amounts of dust if they're in these areas.

Wikipedia : 74 Coccidioidomycosis (/k?k?s?di??do?ma?'ko?s?s/, kok-sid-ee-oy-doh-my-KOH-sis), commonly known as cocci,... more...

Related Diseases for Coccidioidomycosis

Diseases related to Coccidioidomycosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 589)
# Related Disease Score Top Affiliating Genes
1 coccidiosis 34.0 TLR4 IL17A CD40LG CD4 CCR6
2 cryptosporidiosis 32.5 TLR4 MBL2 CD40LG CD4
3 osteomyelitis 31.2 TLR4 STAT1 IFNGR1
4 west nile encephalitis 30.7 CD40LG CD4
5 exanthem 30.7 CD40LG CD4 CCR6
6 histoplasmosis 30.7 STAT1 CLEC7A CD40LG CD4 CCR6
7 meningitis 30.7 TLR4 MBL2 IL17A CD40LG
8 yellow fever 30.6 STAT1 IL17A CD40LG CCR6
9 pneumonia 30.6 TLR4 MBL2 IL17A CD40LG
10 stomatitis 30.6 TLR4 CD40LG CD4
11 brucellosis 30.5 TLR4 IL17A CD40LG
12 dysentery 30.5 TLR4 CD40LG CD4 CCR6
13 chorioretinitis 30.4 IL17A CD40LG CD4
14 prosthetic joint infection 30.4 TLR4 MBL2
15 paracoccidioidomycosis 30.3 TLR4 IL12RB1 CD40LG
16 iridocyclitis 30.3 IL17A CD40LG CD4
17 granulomatous dermatitis 30.3 CD40LG CD4
18 aspergillosis 30.2 TLR4 MBL2 CLEC7A CCR6
19 cerebritis 30.2 CD40LG CD4
20 schistosomiasis 30.2 IL17A IFNGR1 CD40LG
21 iritis 30.2 CD40LG CD4 CCR6
22 primary syphilis 30.2 CD40LG CD4
23 suppurative lymphadenitis 30.2 CD4 CCR6
24 spongiotic dermatitis 30.1 CD4 CCR6
25 neuroretinitis 30.1 CD40LG CD4
26 granulomatous hepatitis 30.1 CD40LG CD4
27 mumps 30.1 STAT1 CD69 CD40LG
28 listeriosis 30.1 TLR4 MBL2 CD4 CCR6
29 q fever 30.1 TLR4 MBL2 CD40LG
30 viral encephalitis 30.0 CD40LG CD4 CCR6
31 toxoplasmosis 30.0 TLR4 STAT1 CD40LG
32 allergic hypersensitivity disease 30.0 TLR4 IL17A CD69 CD4 CCR6
33 bronchopneumonia 30.0 TLR4 CD40LG CD4
34 lung disease 29.9 TLR4 MBL2 IL17A IFNGR1 CD40LG
35 crohn's disease 29.9 TLR4 IL17A CD4 CCR6
36 syphilis 29.9 IL17A CD40LG CD4 CCR6
37 amebiasis 29.9 TLR4 IL17A CD40LG CD4
38 cellulitis 29.9 CD40LG CD4 CCR6
39 bacterial pneumonia 29.9 TLR4 IL17A CD40LG CD4 CCR6
40 sporotrichosis 29.9 CLEC7A CD40LG CD4 CARD9
41 bronchiolitis 29.9 TLR4 IL17A CD40LG
42 myelitis 29.9 IL17A CD40LG CCR6
43 contact dermatitis 29.9 TLR4 IL17A CD4
44 myocarditis 29.9 TLR4 IL17A IL12RB1 CD40LG
45 meningoencephalitis 29.8 CD40LG CD4 CCR6 CARD9
46 nocardiosis 29.8 IL12RB1 IFNGR1 CD4
47 testicular disease 29.7 TLR4 CD40LG CD4 CCR6
48 lymphadenitis 29.7 TLR4 IL12RB1 IFNGR1 CD4 CCR6
49 leprosy 3 29.7 TLR4 IL17A CD40LG CD4 CCR6
50 autoimmune disease 29.7 MBL2 IL17A CD69 CD40LG CCR6

Graphical network of the top 20 diseases related to Coccidioidomycosis:



Diseases related to Coccidioidomycosis

Symptoms & Phenotypes for Coccidioidomycosis

Symptoms:

12
  • arthritis
  • chest pain
  • conjunctivitis

UMLS symptoms related to Coccidioidomycosis:


fever, pruritus

MGI Mouse Phenotypes related to Coccidioidomycosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 CARD9 CCR6 CD4 CD40LG CD69 CLEC4E
2 digestive/alimentary MP:0005381 9.8 CD4 CLEC7A CYP51A1 IFNGR1 IL17A STAT1
3 homeostasis/metabolism MP:0005376 9.77 CARD9 CCR6 CD4 CD40LG CLEC4E CLEC7A
4 immune system MP:0005387 9.5 CARD9 CCR6 CD4 CD40LG CD69 CLEC4E

Drugs & Therapeutics for Coccidioidomycosis

Drugs for Coccidioidomycosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 20)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
2
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
3 Anti-Infective Agents Phase 4
4 Cytochrome P-450 Enzyme Inhibitors Phase 4
5 Hormone Antagonists Phase 4
6 Antifungal Agents Phase 4
7 Steroid Synthesis Inhibitors Phase 4
8 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
9 Hormones Phase 4
10
Posaconazole Approved, Investigational, Vet_approved Phase 3 171228-49-2 147912
11
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
12
Itraconazole Approved, Investigational Phase 2, Phase 3 84625-61-6 55283
13 Antiparasitic Agents Phase 3
14 Antiprotozoal Agents Phase 3
15 Cytochrome P-450 CYP3A Inhibitors Phase 3
16
Hydroxyitraconazole Phase 2, Phase 3
17 Vaccines Phase 2
18 Immunologic Factors Phase 2
19 Nikkomycin Phase 1, Phase 2
20
Methotrexate Approved 1959-05-2, 59-05-2 126941

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever) Terminated NCT02663674 Phase 4 Fluconazole
2 Safety, Sensitivity and Specificity of Spherule-derived Coccidioidin in Naive Adults, in Adults With a History of Pulmonary Coccidioidomycosis and in Adults With a History of Pulmonary Histoplasmosis Completed NCT00690092 Phase 3
3 A Multicenter, Randomized, Controlled, Double-Blind, Double-Dummy, Two-Arm Study of Posaconazole vs Fluconazole in the Treatment of Coccidioidomycosis Completed NCT00423267 Phase 3 Posaconazole;Fluconazole
4 Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081) Completed NCT00000676 Phase 3 Clotrimazole;Fluconazole
5 Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI) Recruiting NCT03059992 Phase 3 Ibrexafungerp
6 SUBA-itraconazole Versus Conventional Itraconazole in the Treatment of Endemic Mycoses: a Multi-center, Open-label Comparative Trial Recruiting NCT03572049 Phase 2, Phase 3 SUBA itraconazole;Conventional itraconazole
7 Parts A&B: Evaluation of the Safety and Immunogenicity of Rift Valley Fever Vaccine, Inactivated, Dried (TSI-GSD 200), A Phase 2 Study Completed NCT00584194 Phase 2
8 Safety and Immunogenicity of Live-Attenuated MP-12 Rift Valley Fever Vaccine in Humans, and Genetic Characterization of Virus Isolates Recovered From the Blood of Vaccinated Volunteers: A Phase II Study Completed NCT00415051 Phase 2
9 Bridging Safety & Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine RTS,S/AS01E (0.5 mL Dose) to RTS,S/AS02D (0.5 mL Dose) Administered IM According to a 0, 1, 2-Month Schedule in Gabonese Children Aged 18 Months to 4 Years Completed NCT00307021 Phase 2
10 A Phase IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02D, a Candidate Malaria Vaccine, When Incorporated Into an Expanded Program on Immunization (EPI) Regimen That Includes DTPw/Hib in Infants Living in a Malaria-endemic Region. Completed NCT00289185 Phase 2
11 A Phase 2 Open Label Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated, Dried, TSI-GSD 200, Lot 7, Run 2, in Adult Subjects at Risk of Exposure to Rift Valley Fever Virus Recruiting NCT03609398 Phase 2
12 Long-Term Open-Label Primary Vaccination and Booster Dose Study of the Safety and Immunogenicity of Rift Valley Fever Vaccine, Inactivated, Dried (TSI-GSD 200) in At-Risk Adults Active, not recruiting NCT00869713 Phase 2
13 Phase I/II Evaluation of the Safety, Pharmacokinetics, and Preliminary Effectiveness of Nikkomycin Z in the Treatment of Patients With Uncomplicated Coccidioides Pneumonia Terminated NCT00614666 Phase 1, Phase 2 nikkomycin Z
14 Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis Withdrawn NCT02908334 Phase 2 Sertraline
15 Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine Completed NCT03055000 Phase 1
16 Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis Completed NCT00796809
17 Late Outcomes of Rift Valley Fever in Kenya: Ijara Clinical Survey Completed NCT00287014
18 A Double-Blind, Placebo-Controlled Study of Fluconazole in the Prevention of Active Coccidioidomycosis and Other Systemic Fungal Infections in HIV-Infected Patients Living in the Coccidioidal Endemic Area Completed NCT00002325 Fluconazole
19 Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis Completed NCT00002010 Fluconazole
20 Organ Transplant Infection Prevention and Detection Project 1.0; Cohort Study of Transplant Recipients at "Ultra-High" Risk for Invasive Fungal Infections Completed NCT00177801
21 An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged > / = 14 Years Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (SAnds-PPC) Recruiting NCT03908632
22 The Pathogenesis and Genetics of Disseminated or Refractory Coccidiodomycosis Recruiting NCT02190266
23 Improving the Appearance of Skin and Hair in Patients Undergoing Valley Fever Treatment Active, not recruiting NCT03618992
24 Study of Patients With Parasitic Infections of the Gastrointestinal Tract Terminated NCT00001162

Search NIH Clinical Center for Coccidioidomycosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Fluconazole
Itraconazole
Ketoconazole

Cochrane evidence based reviews: coccidioidomycosis

Genetic Tests for Coccidioidomycosis

Anatomical Context for Coccidioidomycosis

MalaCards organs/tissues related to Coccidioidomycosis:

40
Testes, Skin, Lung, Bone, Liver, T Cells, Prostate

Publications for Coccidioidomycosis

Articles related to Coccidioidomycosis:

(show top 50) (show all 4231)
# Title Authors PMID Year
1
The mysterious desert dwellers: Coccidioides immitis and Coccidioides posadasii, causative fungal agents of coccidioidomycosis. 61 42
30898028 2019
2
Notes from the Field: Multistate Coccidioidomycosis Outbreak in U.S. Residents Returning from Community Service Trips to Baja California, Mexico - July-August 2018. 61 42
30973851 2019
3
The Rise of Valley Fever: Prevalence and Cost Burden of Coccidioidomycosis Infection in California. 61 42
30925716 2019
4
In vitro whole-blood analysis of cellular immunity in patients with active coccidioidomycosis by using the antigen preparation T27K. 54 61
12204956 2002
5
Suspected Locally Acquired Coccidioidomycosis in Human, Spokane, Washington, USA. 61
31922952 2020
6
Methods for successful inactivation of Rift Valley fever virus in infected mosquitoes. 61
31794780 2020
7
Effect of Environmental Temperature on the Ability of Culex tarsalis and Aedes taeniorhynchus (Diptera: Culicidae) to Transmit Rift Valley Fever Virus. 61
32017863 2020
8
Testicular Coccidioidomycosis as the Initial Manifestation of Disseminated Disease. 61
31557487 2020
9
Pulmonary Coccidioidomycosis. 61
32000283 2020
10
Clinical features of cats diagnosed with coccidioidomycosis in Arizona, 2004-2018. 61
30784342 2020
11
A survey of veterinarians' knowledge, attitudes and practices regarding an emerging disease: Coccidioidomycosis in Washington State. 61
31541564 2020
12
Charles Edward Smith: Coccidioidomycologist and public health leader. 61
31965910 2020
13
Environmental factors affecting ecological niche of Coccidioides species and spatial dynamics of valley fever in the United States. 61
32007282 2020
14
Genomic characterization of Parengyodontium americanum sp. Nov. 61
32028048 2020
15
Relative Distribution, Diversity, and Bloodmeal Sources of Mosquitoes and Known Vectors of Rift Valley Fever Phlebovirus in Three Differing Ecosystems in Bura, Tana River County, Kenya. 61
31990632 2020
16
Neutralizing antibodies against Rift Valley fever virus in wild antelope in far northern KwaZulu-Natal, South Africa, indicate recent virus circulation. 61
31943795 2020
17
The challenging management of Rift Valley Fever in humans: literature review of the clinical disease and algorithm proposal. 61
31969141 2020
18
Microencapsulated plasmids expressing Gn and Gc glycoproteins of Rift Valley Fever virus enhance humoral immune response in mice. 61
31983039 2020
19
A comment on 'Seroprevalence of Rift Valley fever in South African domestic and wild suids (1999-2016)'. 61
31898395 2020
20
Lesions and Cellular Tropism of Natural Rift Valley Fever Virus Infection in Young Lambs. 61
31842723 2020
21
Rift Valley fever virus targets the maternal-foetal interface in ovine and human placentas. 61
31961862 2020
22
Zwiesel bat banyangvirus, a potentially zoonotic Huaiyangshan banyangvirus (Formerly known as SFTS)-like banyangvirus in Northern bats from Germany. 61
31992832 2020
23
Infection of Aortic Endograft Caused by Coccidioidomycosis. 61
31351044 2020
24
Infections preceding the development of Dercum disease. 61
31908946 2020
25
Pulmonary Coccidioidomycosis Mimicking Aspergillosis Fungus Ball. 61
31580429 2020
26
Use of Nanotrap particles for the capture and enrichment of Zika, chikungunya and dengue viruses in urine. 61
31910225 2020
27
Finding equipoise: CEPI revises its equitable access policy. 61
32005536 2020
28
Developing vaccines against epidemic-prone emerging infectious diseases. 61
31776599 2020
29
Lyophilized Matrix Containing Ready-to-Use Primers and Probe Solution for Standardization of Real-Time PCR and RT-qPCR Diagnostics in Virology. 61
32019076 2020
30
Elongin C contributes to RNA polymerase II degradation by the interferon antagonist NSs of La Crosse orthobunyavirus. 61
31941775 2020
31
The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 2: Vaccine efficacy studies. 61
31982149 2020
32
Extrapulmonary Coccidioidomycosis Among Children in Central California: A Retrospective Review. 61
31738333 2019
33
Health of African Buffalos (Syncerus caffer) in Ruaha National Park, Tanzania. 61
31833815 2019
34
Sero-Epidemiological Study of Selected Zoonotic and Abortifacient Pathogens in Cattle at a Wildlife-Livestock Interface in South Africa. 61
31841655 2019
35
Early Events in Coccidioidomycosis. 61
31619396 2019
36
North American blastomycosis in an immunocompromised patient. 61
31939939 2019
37
Rift Valley Fever Virus: Propagation, Quantification, and Storage. 61
31763765 2019
38
Mechanisms of inter-epidemic maintenance of Rift Valley fever phlebovirus. 61
31870761 2019
39
Candidate vaccines for human Rift Valley fever. 61
31478397 2019
40
Prevalence and identification of arthropod-transmitted viruses in Kassala state, Eastern Sudan. 61
30716013 2019
41
Common vole (Microtus arvalis) and bank vole (Myodes glareolus) derived permanent cell lines differ in their susceptibility and replication kinetics of animal and zoonotic viruses. 61
31513859 2019
42
Willingness to pay for a Rift valley fever (RVF) vaccine among Kenyan cattle producers. 61
31525647 2019
43
Seroprevalence of Rift Valley fever in cattle of smallholder farmers in Kwilu Province in the Democratic Republic of Congo. 61
31250252 2019
44
Disseminated coccidioidomycosis mimicking cicatricial alopecia. 61
31687463 2019
45
Rescue of infectious Arumowot virus from cloned cDNA: Posttranslational degradation of Arumowot virus NSs protein in human cells. 61
31751340 2019
46
Development of Rift Valley fever (RVF) vaccine by genetic joining of the RVF-glycoprotein Gn with the strong adjuvant subunit B of cholera toxin (CTB) and expression in bacterial system. 61
31762643 2019
47
Antiviral and virucidal activities of Lucilia cuprina maggots' excretion/secretion (Diptera: Calliphoridae): first work. 61
31844722 2019
48
Knowledge, attitudes, and practices regarding coccidioidomycosis among healthcare providers in four counties in Washington State, 2017. 61
31711221 2019
49
Population Structure and Genetic Diversity among Isolates of Coccidioides posadasii in Venezuela and Surrounding Regions. 61
31772050 2019
50
Valley fever on the rise after years of decline in the USA. 61
31657781 2019

Variations for Coccidioidomycosis

Expression for Coccidioidomycosis

Search GEO for disease gene expression data for Coccidioidomycosis.

Pathways for Coccidioidomycosis

Pathways related to Coccidioidomycosis according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.66 TLR4 STAT1 MBL2 IL17A IL12RB1 IFNGR1
2
Show member pathways
13.17 TLR4 STAT1 IL17A IL12RB1 CD40LG CD4
3
Show member pathways
12.34 TLR4 STAT1 IL17A IFNGR1 CD40LG CD4
4
Show member pathways
12.21 CLEC7A CLEC6A CLEC4E CARD9
5
Show member pathways
12.17 TLR4 STAT1 IL17A IL12RB1 IFNGR1 CD4
6
Show member pathways
12.03 TLR4 STAT1 IFNGR1 CD40LG
7
Show member pathways
12 STAT1 CLEC7A CLEC6A CLEC4E CARD9
8
Show member pathways
11.75 STAT1 IL12RB1 CD4
9 11.69 TLR4 STAT1 IFNGR1 CLEC7A CLEC4E CARD9
10
Show member pathways
11.65 TLR4 IL17A IL12RB1
11 11.61 IL17A IL12RB1 CD4 CCR6
12 11.33 CD69 CD40LG CD4
13
Show member pathways
11.21 TLR4 STAT1 IL17A IL12RB1 IFNGR1 CD4

GO Terms for Coccidioidomycosis

Cellular components related to Coccidioidomycosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.5 TLR4 MBL2 CLEC7A CD69 CD40LG CD4
2 external side of plasma membrane GO:0009897 9.17 TLR4 IL17A IL12RB1 CD69 CD40LG CD4

Biological processes related to Coccidioidomycosis according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.8 TLR4 MBL2 CLEC7A CLEC6A CLEC4E CARD9
2 cytokine-mediated signaling pathway GO:0019221 9.77 STAT1 IL17A IL12RB1 IFNGR1 CD4
3 cellular response to interferon-gamma GO:0071346 9.72 TLR4 STAT1 IL12RB1
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.71 TLR4 CLEC6A CD4 CARD9
5 immune response GO:0006955 9.63 TLR4 IL17A CLEC4E CD40LG CD4 CCR6
6 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.56 TLR4 STAT1
7 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.54 CLEC7A CD4
8 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.52 STAT1 IFNGR1
9 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.51 TLR4 CLEC7A
10 positive regulation of interferon-alpha production GO:0032727 9.49 TLR4 STAT1
11 pattern recognition receptor signaling pathway GO:0002221 9.48 CLEC7A CLEC4E
12 negative regulation of amyloid-beta clearance GO:1900222 9.46 IFNGR1 CYP51A1
13 positive regulation of interleukin-12 biosynthetic process GO:0045084 9.43 TLR4 CLEC7A
14 detection of fungus GO:0016046 9.26 TLR4 CLEC7A
15 immune system process GO:0002376 9.17 TLR4 MBL2 CLEC7A CLEC6A CLEC4E CD4
16 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.13 TLR4 IL17A CLEC7A

Molecular functions related to Coccidioidomycosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor activity GO:0038023 9.26 TLR4 CLEC4E CD4 CCR6
2 carbohydrate binding GO:0030246 9.02 MBL2 CLEC7A CLEC6A CLEC4E CD69

Sources for Coccidioidomycosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....